Free Trial
→ DOJ Admits It In Court—Your Cash Can Be Seized Without Warning (From Priority Gold) (Ad)tc pixel
NYSEAMERICAN:MAIA

MAIA Biotechnology Q3 2025 Earnings Report

MAIA Biotechnology logo
$1.34 -0.02 (-1.10%)
As of 09:49 AM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings History

MAIA Biotechnology EPS Results

Actual EPS
-$0.27
Consensus EPS
-$0.19
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

MAIA Biotechnology Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

MAIA Biotechnology Announcement Details

Quarter
Q3 2025
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
Friday, November 7, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

MAIA Biotechnology's Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

MAIA Biotechnology's Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

MAIA Biotechnology Earnings Headlines

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST) and MAIA Biotechnology, Inc. (MAIA)
June 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/WST/pressreleases/2283267/analysts-offer-insights-on-healthcare-companies-west-pharmaceutical-services-wst-and-maia-biotechnology-inc-maia/
MAIA Biotechnology opens second US site for THIO-101 trial
June 11, 2026  |  yahoo.comhttps://www.yahoo.com/news/science/articles/maia-biotechnology-opens-second-us-105853880.html
This Could Be the Biggest Monetary Shift in 50 Years
Tucked inside U.S. Code Title 31, Section 5117 is a provision allowing the Treasury to reprice America's gold reserves from $42 per ounce to today's market value - a potential 107x shift. President Trump has signaled interest in returning the dollar to commodity-backed foundations. More than 60 million Americans can move a portion of their savings into physical gold, tax-free and penalty-free, before any policy change is announced. The 2026 Gold Guide explains exactly how to position your 401(k) or IRA outside the dollar-denominated system.tc pixel
June 16 at 1:00 AM  |  Americas Gold Company (Ad)
MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3309785/0/en/maia-biotechnology-activates-and-opens-enrollment-at-second-u-s-clinical-site-for-international-phase-2-thio-101-expansion-trial.html
MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial
June 4, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/04/3306880/0/en/maia-biotechnology-reports-strong-enrollment-and-dosing-momentum-in-pivotal-phase-3-non-small-cell-lung-cancer-trial.html
MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion
June 3, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/03/3306173/0/en/maia-biotechnology-receives-fda-clearance-to-open-u-s-enrollment-in-ongoing-phase-2-thio-101-trial-expansion.html
See More MAIA Biotechnology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MAIA Biotechnology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MAIA Biotechnology and other key companies, straight to your email.

About MAIA Biotechnology

MAIA Biotechnology (NYSEAMERICAN:MAIA) is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods. In parallel, MAIA Biotechnology is advancing therapeutic constructs that couple monoclonal antibodies to therapeutic radioisotopes for selective tumor cell eradication. These efforts are supported by in‐house radiochemistry capabilities and collaborative research partnerships with academic institutions.

Headquartered in the United States, MAIA Biotechnology serves both domestic and international research markets and is preparing key assets for regulatory submission and first‐in‐human trials. The management team comprises industry veterans in radiopharmaceutical development and antibody engineering, and the company continues to expand its platform technology to address unmet needs in cancer diagnosis and treatment.

View MAIA Biotechnology Profile
Earnings Tools